Branimir I. Šikić

机构：Stanford Medicine, Stanford University · ORCID：0000-0001-6814-2070

发表论文 351 篇 · 总被引 21820 次 · h-index 65

代表论文

Carboplatin-induced upregulation of pan β-tubulin and class III β-tubulin is implicated in acquired resistance and cross-resistance of ovarian cancer (2023 · Cellular and Molecular Life Sciences · 被引 15)
A Phase I Trial of the ABCB1 Inhibitor, Oral Valspodar, in Combination With Paclitaxel in Patients With Advanced Solid Tumors (2023 · American Journal of Clinical Oncology · 被引 8)
Continuous 72-h infusion of zosuquidar with chemotherapy in patients with newly diagnosed acute myeloid leukemia stratified for leukemic blast P-glycoprotein phenotype (2024 · Cancer Chemotherapy and Pharmacology · 被引 6)
A clinical trial of zosuquidar plus gemtuzumab ozogamicin (GO) in relapsed or refractory acute myeloid leukemia (RR AML): evidence of efficacy based on leukemic blast P-glycoprotein functional phenotype (2023 · Cancer Chemotherapy and Pharmacology · 被引 5)
Editorial Expression of Concern: Decreased levels of baseline and drug-induced tubulin polymerisation are hallmarks of resistance to taxanes in ovarian cancer cells and are associated with epithelial-to-mesenchymal transition (2025 · British Journal of Cancer)
Supplementary Table 1 and Supplementary Figures 1 through 5 from Mechanisms of Resistance to Cabazitaxel (2023)